Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Enliven Therapeutics Inc., 3 years.
Enliven Therapeutics Inc.
Director
Kura Oncology Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 17, 2026 | Enliven Therapeutics Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Sep 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −2,916 | $50.03 | $145,891 |
| Sep 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −1,844 | $50.71 | $93,507 |
| Sep 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −240 | $51.48 | $12,356 |
| Aug 17, 2026 | Enliven Therapeutics Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −3,900 | $58.37 | $227,650 |
| Aug 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −1,100 | $59.35 | $65,281 |
| Jul 17, 2026 | Enliven Therapeutics Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Jul 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −231 | $50.05 | $11,563 |
| Jul 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −459 | $51.55 | $23,660 |
| Jul 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −2,063 | $52.39 | $108,085 |
| Jul 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −2,184 | $53.42 | $116,669 |
| Jul 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −63 | $53.92 | $3,397 |
| Jun 17, 2026 | Enliven Therapeutics Inc. | Option exercise | +5,000 | $2.48 | $12,400 |
| Jun 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −1,268 | $42.83 | $54,308 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.